Multiple Myeloma

- CCT5046
  Phase I
  CC-98633 BCMA
  Targeted NEX-T CAR T Cells, in Relapsed and/or Refractory Multiple Myeloma
  PI: Liedtke
  Sponsor: Pending

- CCT5030
  Phase I
  ALLO-715 Eval Anti-BCMA Allogene CAR T Cell Tx in Relapsed/Refractory Multiple Myeloma
  PI: Liedtke
  Sponsor: Allogene

- CCT5025
  Phase III bb2121 vs SoC Triplet Regimens in Relapsed & Refractory Multiple Myeloma (RRMM)
  (KarMMa-3)
  PI: Liedtke
  Sponsor: Pending

- Enrolled in HEMMYL0025

- HEMMYL0026
  Phase I Longterm Follow-up of Subjects Treated with bb2121
  PI: Liedtke
  Sponsor: Seattle Genetics

KEY

- Pending
- Open for Enrollment
- Link
- Optional Path
- Enrollment on Hold
- Trial Posting
- Extension Study
- Immunotherapy

Please mark up a copy using black ink and send changes to SRC-office@stanford.edu